NO20091296L - Fremgangsmate for behandling av slag med trombolytisk middel - Google Patents

Fremgangsmate for behandling av slag med trombolytisk middel

Info

Publication number
NO20091296L
NO20091296L NO20091296A NO20091296A NO20091296L NO 20091296 L NO20091296 L NO 20091296L NO 20091296 A NO20091296 A NO 20091296A NO 20091296 A NO20091296 A NO 20091296A NO 20091296 L NO20091296 L NO 20091296L
Authority
NO
Norway
Prior art keywords
procedure
treatment
dose
thrombolytic agents
human
Prior art date
Application number
NO20091296A
Other languages
English (en)
Other versions
NO342302B1 (no
Inventor
Peter Kuebler
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091296(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20091296L publication Critical patent/NO20091296L/no
Publication of NO342302B1 publication Critical patent/NO342302B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Sammendrag Fremgangsmåte for behandling av akutt, iskemisk slag hos et menneske, som omfatter administrering av tenekteplase til mennesket i en totaldose på omtrent 0,05 til 0,5 mg/kg, gitt som (a) en initiell bolusdose på omtrent 0,0 I 5 til 0,15 mg/kg, fulgt av infusjon av en mengde som er lik totaldosen minus den initielle dosen, i løpet av en periode på omtrent 50-90 minutter, eller (b) en bolus. Sett for utførelse av denne fremgangsmåten er også beskrevet. (Fig. 1)
NO20091296A 2006-08-29 2009-03-27 Tenekteplase for anvendelse ved behandling av akutt, iskemisk slag hos et menneske NO342302B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29
PCT/US2007/074997 WO2008027687A2 (en) 2006-08-29 2007-08-01 Use of tenecteplase for treating acute ischemic stroke

Publications (2)

Publication Number Publication Date
NO20091296L true NO20091296L (no) 2009-05-28
NO342302B1 NO342302B1 (no) 2018-04-30

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091296A NO342302B1 (no) 2006-08-29 2009-03-27 Tenekteplase for anvendelse ved behandling av akutt, iskemisk slag hos et menneske

Country Status (22)

Country Link
US (2) US20080107641A1 (no)
EP (1) EP2056856B1 (no)
JP (1) JP5785687B2 (no)
KR (1) KR20090045405A (no)
CN (1) CN101505785A (no)
AU (1) AU2007290277B2 (no)
BR (1) BRPI0716143A2 (no)
CA (1) CA2661012C (no)
CO (1) CO6150188A2 (no)
EA (1) EA015573B1 (no)
EC (1) ECSP099178A (no)
HK (1) HK1131054A1 (no)
IL (2) IL196987A (no)
MX (1) MX2009001918A (no)
MY (1) MY163119A (no)
NO (1) NO342302B1 (no)
NZ (1) NZ574767A (no)
SG (3) SG10201804944XA (no)
TW (1) TWI439282B (no)
UA (1) UA97486C2 (no)
WO (1) WO2008027687A2 (no)
ZA (1) ZA200900957B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2006229688B2 (en) 2005-02-24 2012-07-26 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
SG10201804944XA (en) 2006-08-29 2018-07-30 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
CN102264290A (zh) * 2008-12-24 2011-11-30 皇家飞利浦电子股份有限公司 具有mr中风检测和治疗的用于心脏介入的系统、方法和设备
AU2010263245A1 (en) 2009-06-22 2012-01-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
AU2010289838C1 (en) * 2009-08-24 2014-03-06 Hough Ear Institute Methods for treating acute acoustic trauma
CA2801292C (en) 2010-06-02 2019-01-22 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
EA026017B1 (ru) * 2010-12-23 2017-02-28 Геннова Байофармасьютикалз Лтд. Фармацевтические композиции тенектеплазы
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
JP6437517B2 (ja) 2013-03-15 2018-12-12 インセラ セラピューティクス，インク． 血管治療装置及び方法
US8690907B1 (en) 2013-03-15 2014-04-08 Insera Therapeutics, Inc. Vascular treatment methods
WO2017142874A2 (en) 2016-02-16 2017-08-24 Insera Therapeutics, Inc. Aspiration devices and anchored flow diverting devices
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
MX2017004470A (es) * 2014-10-21 2017-11-20 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa).
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用
US20180206867A1 (en) * 2017-01-24 2018-07-26 Ekos Corporation Method for the treatment of thromboembolism
WO2018210860A1 (en) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2021158799A1 (en) * 2020-02-04 2021-08-12 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE10199044I2 (de) 1992-06-03 2006-02-09 Genentech Inc Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
SG10201804944XA (en) 2006-08-29 2018-07-30 Genentech Inc Use of tenecteplase for treating acute ischemic stroke

Also Published As

Publication number Publication date
NO342302B1 (no) 2018-04-30
CA2661012A1 (en) 2008-03-06
IL248176A0 (en) 2016-11-30
UA97486C2 (ru) 2012-02-27
AU2007290277B2 (en) 2013-04-11
MY163119A (en) 2017-08-15
WO2008027687A2 (en) 2008-03-06
AU2007290277A1 (en) 2008-03-06
JP5785687B2 (ja) 2015-09-30
US20080107641A1 (en) 2008-05-08
CN101505785A (zh) 2009-08-12
CO6150188A2 (es) 2010-04-20
BRPI0716143A2 (pt) 2013-11-26
SG10201804944XA (en) 2018-07-30
SG174753A1 (en) 2011-10-28
ZA200900957B (en) 2010-05-26
US20120164157A1 (en) 2012-06-28
EA015573B1 (ru) 2011-10-31
MX2009001918A (es) 2009-03-06
TW200817033A (en) 2008-04-16
HK1131054A1 (en) 2010-01-15
EP2056856B1 (en) 2015-01-14
US9023346B2 (en) 2015-05-05
CA2661012C (en) 2019-03-19
NZ574767A (en) 2012-02-24
TWI439282B (zh) 2014-06-01
IL196987A0 (en) 2011-08-01
EA200970237A1 (ru) 2009-08-28
JP2010502629A (ja) 2010-01-28
EP2056856A2 (en) 2009-05-13
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31
KR20090045405A (ko) 2009-05-07
WO2008027687A3 (en) 2008-05-22
SG10201501498VA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
NO20092569L (no) Inhibitorer av Akt-aktivitet
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
WO2008106058A3 (en) Inhibitors of serine proteases
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008017025A3 (en) Combination therapy
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
EP2279244A4 (en) METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
NO20063842L (no) Silinanforbindelser som cysteinproteaseinhibitorer
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NO20083836L (no) N-hydroksyakrylamidforbindelser
EA202193019A1 (ru) Лечение наследственного ангионевротического отека
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2009005798A (es) Recuperacion de apoplejia.
WO2007047205A8 (en) Enzyme inhibitors of pai-1
NO20083928L (no) Anvendelse av TPO-peptidforbindelser og farmasoytiske sammensetninger i behandling av anemi
WO2007081808A3 (en) Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
TW200633720A (en) Medicinal composition for diabetic